UB Paderborn / Katalog / Suche / in CDI

1 – 15 von 15

Sortiert nach

Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.TPS4594-TPS4594

2017

Volltextzugriff (PDF)

Design and analysis of clinical trials in the presence of delayed treatment effect

Statistics in medicine, 2016-05, Vol.35 (11), p.1774-1779

2016

Volltextzugriff (PDF)

Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma

British journal of haematology, 2018-08, Vol.182 (4), p.583-586

2018

Volltextzugriff (PDF)

SURPASS-2 trial design: A phase 2, open-label study of ADP-A2M4CD8 SPEAR T cells in advanced esophageal or esophagogastric junction cancers

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.TPS363-TPS363

2022

Volltextzugriff (PDF)

A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas

Clinical cancer research, 2011-11, Vol.17 (21), p.6831-6839

2011

Volltextzugriff (PDF)

Avelumab (MSB0010718C; anti-PD-L1) in combination with axitinib as first-line treatment for patients with advanced renal cell carcinoma

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS4580-TPS4580

2016

Volltextzugriff (PDF)

Avelumab (MSB0010718C; anti-PD-L1) ± pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone in patients with platinum-resistant/refractory ovarian cancer: The phase III JAVELIN Ovarian 200 trial

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS5600-TPS5600

2016

Volltextzugriff (PDF)

p53 autoantibodies predict subsequent development of cancer

International journal of cancer, 2005-03, Vol.114 (1), p.157-160

2005

Volltextzugriff (PDF)

Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab (R-InO) versus chemotherapy for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL)

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.8529-8529

2014

Volltextzugriff (PDF)

Bayesian Analysis of Serial Dilution Assays

Biometrics, 2004-06, Vol.60 (2), p.407-417

2004

Volltextzugriff (PDF)

A Phase 1 study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor in patients with refractory solid tumor malignancies and lymphomas

Clinical cancer research, 2011-09, Vol.17 (21), p.6831-6839

2011

Volltextzugriff (PDF)

Effect of Teduglutide in Patients with Moderate-Severe Crohnʼs Disease after 20 Weeks of Daily Therapy: 1190

The American journal of gastroenterology, 2006-09, Vol.101, p.S463

2006

Volltextzugriff (PDF)

Abstract A110: A phase 1 study of PF-04929113 (SNX5422), an orally bioavailable heat shock protein 90 (Hsp90) inhibitor administered twice weekly in patients with refractory solid tumor malignancies and lymphoma

Molecular cancer therapeutics, 2009-12, Vol.8 (12_Supplement), p.A110-A110

2009

Volltextzugriff (PDF)

New approaches to modelling and analyzing recurrent event time data

Shnaidman, Michael

2005

Volltextzugriff (PDF)

Liver X Receptor α Is a Transcriptional Repressor of the Uncoupling Protein 1 Gene and the Brown Fat Phenotype

Molecular and Cellular Biology, 2008-04, Vol.28 (7), p.2187-2200

2008

Volltextzugriff (PDF)

1 – 15 von 15

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(14)
Mit Volltextzugriff
(13)

Publikationsform

Artikel
(14)
Dissertationen
(1)

Sprache

Englisch
(15)
Japanisch
(1)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101)

Design and analysis of clinical trials in the presence of delayed treatment effect

Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma

SURPASS-2 trial design: A phase 2, open-label study of ADP-A2M4CD8 SPEAR T cells in advanced esophageal or esophagogastric junction cancers

A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas

Avelumab (MSB0010718C; anti-PD-L1) in combination with axitinib as first-line treatment for patients with advanced renal cell carcinoma

Avelumab (MSB0010718C; anti-PD-L1) ± pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone in patients with platinum-resistant/refractory ovarian cancer: The phase III JAVELIN Ovarian 200 trial

p53 autoantibodies predict subsequent development of cancer

Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab (R-InO) versus chemotherapy for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL)

Bayesian Analysis of Serial Dilution Assays

A Phase 1 study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor in patients with refractory solid tumor malignancies and lymphomas

Effect of Teduglutide in Patients with Moderate-Severe Crohnʼs Disease after 20 Weeks of Daily Therapy: 1190

Abstract A110: A phase 1 study of PF-04929113 (SNX5422), an orally bioavailable heat shock protein 90 (Hsp90) inhibitor administered twice weekly in patients with refractory solid tumor malignancies and lymphoma

New approaches to modelling and analyzing recurrent event time data

Liver X Receptor α Is a Transcriptional Repressor of the Uncoupling Protein 1 Gene and the Brown Fat Phenotype

Suchergebnisse filtern